| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CEO | Director | Executive Chairman
1 company
Tony Cataldo last filed a Form 4 in June 2020, as CEO at GTBP. Tony Cataldo's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 6,500,000 shares of GTBP. The GTBP filings lean toward selling, a net 5,034,320 shares.
Tony Cataldo has 4 Form 4 filings on record from September 2017 to June 2020, all as CEO at GT Biopharma (GTBP), 2017–2020.
The 7 reported transactions were 3 gifts, 2 open-market sales and 2 stock awards.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $5K.
The largest open-market sale was 4,234,320 shares of GTBP at an average $0.00 on June 2, 2020, about $4K.
Shares as reported in the last Form 4 for each company; the most recent is from June 2020. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.